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Background 59
Since the completion of the human genome project in 2003 [1], the biomedical 60 industry has embarked on a journey to demystify the causal links between one's 61 genes, the surrounding environment, and disease. Now, the adventure that began in 62 the genome era has entered the "Big Data" era. The linkage between biobanks that 63 store genetic data and health databases that store electronic medical record (EMR) 64 has been taken as a catalyst to boost biomedical research and to bring us a step closer 65 to precision medicine. The PMI-CP in the U.S., the 100,000 Genomes Project from 66
Genomics England in the U.K, and the China Kadoorie Biobank in China are some of 67 the ambitious national projects exemplifying said trend [2, 3] . Protection Act (PDPA), the accessibility of EMR stored in National Health Insurance 76
Database ("NHID") is very difficult, which may limit and be necessary for BIIP 77 Court responded that said use is permissible because it was related to NHIB's 102   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 identified, the anonymization measure applied by NHIB was sufficient to minimize 104 risk of undue exposure. The Court also emphasized that a personal entitlement to 105 privacy protection is not an absolute legal interest by nature, and may have to yield 106 for comparatively bigger public interest when necessary. 107 108 Nonetheless, uncertainty remains after the Court's ruling. While human right groups 109 continue questioning the legitimacy of academic access to NHID data, whether a for-110 profit organization, such as a pharmaceutical company, may ask for the similar access 111 has yet to be clarified as well. Without these PDPA issues being resolved, it becomes 112 challenging for Taiwan Biobank to develop a legally admissible cross database 113 convergence scheme, so as to assist MOHW in complementing the BIIP goals. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 already fit into the "prior personal consent with autonomy" exemption. Article 6 of PDPA: Personal information of medical records, medical treatment, genetic information, sexual life, health examination and criminal records should not be collected, processed or used. However, the following situations are not subject to the limits set in the preceding sentence: 1. when in accordance with law; 2. when it is necessary for a government agency to perform its legal duties or for a non-government agency to fulfill its legal obligation, and proper security measures are adopted prior or subsequent to such collection, processing or use; 3. when the Party has made public such information by himself, or when the information concerned has been publicized legally; 4. where it is necessary to perform statistical or other academic research, a government agency or an academic research institution collects, processes, or uses personal information for the purpose of medical treatment, public health, or crime prevention. The information may not lead to the identification of a specific person after its processing by the provider, or from the disclosure by the collector; 5. where it is necessary to assist a government agency in performing its legal duties or a non-government agency in fulfilling its legal obligations, and proper security measures are adopted prior or subsequent to such collection, processing, or use; 6. where the Party has consented in writing; unless such consent exceeds the necessary scope of the specific purpose; the collection, processing or use merely with the consent of the Party is prohibited by other statutes; or such consent is against the Party's will. 135
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Certainly, the informed consent by itself may not be deemed as a substitute of full 136 Ethical, Legal & Social Implication (ELSI) compliance. This is especially true when 137 the informed consent obtained by Taiwan Biobank has been a "broad" one; and the 138 consent has been "for future research" in a general sense. Besides, to facilitate the use 139 of biobank, the collected tissues and data need not be de-linked forever. Thus, subject 140 to Taiwan's Human Biobank Management Act (HBMA) in 2010, the participants have 141 been asked to grant Taiwan Biobank the privilege to maintain the "irretrievability" of 142 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 convergence in various settings among genetic, environmental and EMR. 169
Nonetheless, the rigid protection of privacy has become great obstacle for biobank to 170 access health database. This article believes a consent-based approach will help ease 171 up the concern over violation of PDPA, and clear up the path for making NHID 172 accessible for research purpose. Further, with more and more national biobanks like 173 PMI-CP and UK Biobank established, the need for establishing a unified regional or 174 international standard to make sure interoperability of EMR will be on the rise. 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64Table 1 : Article 6 of Persona Data Protection Act ("PDPA") Personal information like medical records, medical treatment, genetic information, sexual life, health examination and criminal records, etc., is sensitive in nature.
Article 6 of PDPA provides that such information, in general, shall not be collected, processed, or used. Article 6 of PDPA enlists six exceptions to this restriction.
Article 6 of PDPA:
Personal information of medical records, medical treatment, genetic information, sexual life, health examination and criminal records should not be collected, processed or used. However, the following situations are not subject to the limits set in the preceding sentence:
1. when in accordance with law; 2. when it is necessary for a government agency to perform its legal duties or for a non-government agency to fulfill its legal obligation, and proper security measures are adopted prior or subsequent to such collection, processing or use; 3. when the Party has made public such information by himself, or when the information concerned has been publicized legally;
4. where it is necessary to perform statistical or other academic research, a government agency or an academic research institution collects, processes, or uses personal information for the purpose of medical treatment, public health, or crime prevention. The information may not lead to the identification of a specific person after its processing by the provider, or from the disclosure by the collector; 5. where it is necessary to assist a government agency in performing its legal duties or a non-government agency in fulfilling its legal obligations, and proper security measures are adopted prior or subsequent to such collection, processing, or use; 6. where the Party has consented in writing; unless such consent exceeds the necessary scope of the specific purpose; the collection, processing or use merely with the consent of the Party is prohibited by other statutes; or such consent is against the Party's will. Click here to download Table Table 1 Article 6 of PDPA.doc One of the key features of hash function is that the algorithm will transform the identifiable personal data to a unique 128-character code. Taiwan Biobank will develop and enter into a protocol with NHID and adopt hash function framework. When there is need to access the EMR in NHID, all the identifiable data processed will be replaced by hash value returned by hash function, so the access of EMR will be proceeded in a de-identified manner. Figure  Click here to download Figure Figure 2 hashfunction framwork.doc
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